Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mauna Kea Technologies (STU:1MK) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Mauna Kea Technologies Forward PE Ratio Related Terms
Mauna Kea Technologies Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Mauna Kea Technologies's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mauna Kea Technologies Forward PE Ratio Chart
Mauna Kea Technologies Annual Data
Trend
2025-12
Forward PE Ratio
0.56
Mauna Kea Technologies Semi-Annual Data
2025-12
Forward PE Ratio
0.56
STU:1MK vs ABT, SYK, MDT: Forward PE Ratio Comparison
For the Medical Devices subindustry, Mauna Kea Technologies's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mauna Kea Technologies Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mauna Kea Technologies's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Mauna Kea Technologies's Forward PE Ratio falls into.
Mauna Kea Technologies Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Mauna Kea Technologies (STU:1MK) has a Forward PE Ratio of 3.06 as of Sep. 01, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Mauna Kea Technologies and its competitors. According to the industry distribution chart, Mauna Kea Technologies ranks #6 out of 391 companies in the Medical Devices & Instruments industry, placing it in the top 1.5%.
Is Mauna Kea Technologies' Forward PE Ratio too high?
Mauna Kea Technologies' current Forward PE Ratio is 3.06. The Medical Devices & Instruments industry median Forward PE Ratio is 20.18. Mauna Kea Technologies' value of 3.06 is 84.8% below this industry median. Based on the distribution chart, Mauna Kea Technologies ranks #6 out of 391 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Mauna Kea Technologies has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mauna Kea Technologies' Forward PE Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Mauna Kea Technologies ranks #6 out of 391 companies for Forward PE Ratio. This places Mauna Kea Technologies in the top 2% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 20.18. Mauna Kea Technologies' value of 3.06 is 84.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 20.18, based on 391 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mauna Kea Technologies's current Forward PE Ratio of 3.06 is 84.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Mauna Kea Technologies and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 20.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mauna Kea Technologies's current Forward PE Ratio is 3.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mauna Kea Technologies stock overvalued right now?
Based on GuruFocus' analysis, Mauna Kea Technologies (STU:1MK) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.11, compared to a current price of €0.15 — trading 39.3% above its estimated fair value. The current Forward PE Ratio is 3.06 and 84.8% below the Medical Devices & Instruments industry median of 20.18. Mauna Kea Technologies' overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Mauna Kea Technologies (STU:1MK), the current Forward PE Ratio is 3.06 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mauna Kea Technologies (STU:1MK) Overvalued in 2026?
Based on GuruFocus' analysis, Mauna Kea Technologies stock appears to be overvalued.
The current stock price of €0.15 is trading 39.3% above its estimated GF Value™ of €0.11.
GuruFocus considers Mauna Kea Technologies to be Significantly Overvalued.
Key valuation signals for STU:1MK:
Forward PE Ratio: 3.06
GF Value™: €0.11 vs. price of €0.15 (39.3% above fair value)
Industry Position: 84.8% below the Medical Devices & Instruments median (#6 of 391)
No single metric tells the full story. See the STU:1MK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mauna Kea Technologies SA is a medical device company that develops, manufactures and markets an imaging platform for visualizing tissue at the cellular level, in real time, during standard procedures, with the mission of eliminating uncertainties in diagnosis and treatment through direct visualization of tissue in vivo at the microscopic level. The company's flagship product, Cellvizio, is the smallest microscope, designed for direct use during minimally invasive procedures. It operates in a single business segment: endomicroscopy. Its geographical presence includes EMEA (Europe, Middle East, Africa), USA and Canada, and Asia, of which the majority of the revenue is generated from USA and Canada.
47GF Score
Get the complete analysis for STU:1MK
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1MK has been successfully added to your 
